Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Steven Pieper sold 17,400 shares of Xeris Biopharma stock in a transaction on Monday, July 6th. The stock was sold at an average price of $8.50, for a total value of $147,900.00. Following the completion of the sale, the insider directly owned 1,393,653 shares of the company’s stock, valued at $11,846,050.50. The trade was a 1.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Pieper also recently made the following trade(s):
- On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00.
Xeris Biopharma Price Performance
Shares of Xeris Biopharma stock opened at $8.94 on Wednesday. The stock’s fifty day moving average is $6.71 and its 200 day moving average is $6.65. Xeris Biopharma Holdings, Inc. has a one year low of $4.66 and a one year high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The stock has a market cap of $1.54 billion, a P/E ratio of 149.00 and a beta of 0.62.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $10.80.
Check Out Our Latest Analysis on XERS
Institutional Trading of Xeris Biopharma
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its position in Xeris Biopharma by 21.8% in the first quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock worth $5,072,000 after buying an additional 156,483 shares during the last quarter. Janus Henderson Group PLC increased its position in Xeris Biopharma by 322.8% during the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock valued at $1,713,000 after acquiring an additional 225,602 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Xeris Biopharma by 19.3% in the first quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock valued at $1,046,000 after acquiring an additional 29,168 shares during the period. Royal Bank of Canada raised its stake in shares of Xeris Biopharma by 12.9% in the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock valued at $253,000 after acquiring an additional 4,974 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Xeris Biopharma by 59.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock worth $422,000 after acquiring an additional 27,003 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.
About Xeris Biopharma
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Articles
- Five stocks we like better than Xeris Biopharma
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
